FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1777661785> ?p ?o ?g. }

• W1777661785 endingPage "37" @default.
• W1777661785 startingPage "1629" @default.
• W1777661785 abstract "Temozolomide (TMZ) is an oral imidazotetrazinone that is spontaneously converted to 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC) at physiological pH. MTIC methylates DNA at the O6 position of guanine, although this lesion may be repaired by the enzyme O6-alkylguanine-DNA alkyltransferase (AGAT). In this study, TMZ was combined with cisplatin (CDDP), because both agents have single-agent activity against melanoma and other tumor types. Additionally, CDDP has been shown to inactivate AGAT, and subtherapeutic concentrations of CDDP have been shown to increase the sensitivity of leukemic blasts to TMZ. This Phase I study sought to determine the toxicities, recommended dose, and pharmacological profile of the TMZ/CDDP combination. Patients were treated with oral TMZ daily for 5 consecutive days together with CDDP on day 1 (4 h after TMZ) every 4 weeks at the following TMZ (mg/m2/day)/CDDP (mg/m2) dose levels: 100/75, 150/75, 200/75, and 200/100. Plasma samples were obtained on days 1 and 2 to evaluate the pharmacokinetic parameters of TMZ alone and in combination with CDDP. Fifteen patients received a total of 44 courses of TMZ/CDDP. The principal toxicities of the regimen consisted of neutropenia, thrombocytopenia, nausea, and vomiting, which were intolerable in two of six new patients treated at the 200/100 mg/m2 dose level. Of five patients receiving 17 courses at the next lower dose level (200/75 mg/m2), none experienced dose-limiting toxicity. Antitumor activity was observed in patients with non-small cell lung cancer, squamous cell carcinoma of the tongue, and leiomyosarcoma of the uterus. Pharmacokinetic studies of TMZ revealed the following pertinent parameters (mean +/- SD): time to maximum plasma concentration (Tmax) = 1.1+/-0.6 h (day 1) and 1.7+/-0.9 h (day 2); elimination half-life (t1/2) = 1.74+/-0.22 h (day 1) and 2.35+/-0.70 h (day 2); and clearance (Cl(s)/F) = 115+/-27 ml/min/m2 (day 1) and 141+/-109 ml/min/m2 (day 2). TMZ drug exposure, described by the area under the plasma concentration-time curve (AUCinfinity) and the maximum plasma concentration (Cmax), was similar on days 1 and 2. On the basis of these results, the recommended doses for Phase II clinical trials are TMZ 200 mg/m2/day for 5 days with 75 mg/m2 CDDP on day 1, every 4 weeks. The addition of CDDP did not affect the tolerable dose of single-agent TMZ (200 mg/m2/day x 5 days), nor did it substantially alter the pharmacokinetic behavior of TMZ." @default.
• W1777661785 created "2016-06-24" @default.
• W1777661785 creator A5002037553 @default.
• W1777661785 creator A5005738281 @default.
• W1777661785 creator A5008690308 @default.
• W1777661785 creator A5011905014 @default.
• W1777661785 creator A5015548619 @default.
• W1777661785 creator A5038259200 @default.
• W1777661785 creator A5052493398 @default.
• W1777661785 creator A5058784740 @default.
• W1777661785 creator A5060360003 @default.
• W1777661785 creator A5060438424 @default.
• W1777661785 creator A5071938679 @default.
• W1777661785 creator A5077260725 @default.
• W1777661785 creator A5079101064 @default.
• W1777661785 creator A5080900202 @default.
• W1777661785 date "1999-07-01" @default.
• W1777661785 modified "2023-09-27" @default.
• W1777661785 title "A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies." @default.
• W1777661785 cites W1525505117 @default.
• W1777661785 cites W1575812451 @default.
• W1777661785 cites W1576871010 @default.
• W1777661785 cites W1579641819 @default.
• W1777661785 cites W1602252590 @default.
• W1777661785 cites W1637771339 @default.
• W1777661785 cites W1835101589 @default.
• W1777661785 cites W1861898234 @default.
• W1777661785 cites W1923472835 @default.
• W1777661785 cites W1967588280 @default.
• W1777661785 cites W1971921783 @default.
• W1777661785 cites W1973027090 @default.
• W1777661785 cites W1976336159 @default.
• W1777661785 cites W1980195588 @default.
• W1777661785 cites W1987760594 @default.
• W1777661785 cites W1992644438 @default.
• W1777661785 cites W2008507360 @default.
• W1777661785 cites W2011819340 @default.
• W1777661785 cites W2067210803 @default.
• W1777661785 cites W2068220280 @default.
• W1777661785 cites W2075034527 @default.
• W1777661785 cites W2076176285 @default.
• W1777661785 cites W2079203845 @default.
• W1777661785 cites W2079786467 @default.
• W1777661785 cites W2094502901 @default.
• W1777661785 cites W2109549713 @default.
• W1777661785 cites W2124105384 @default.
• W1777661785 cites W2129146015 @default.
• W1777661785 cites W2129160559 @default.
• W1777661785 cites W2193745126 @default.
• W1777661785 cites W2308844187 @default.
• W1777661785 cites W235444781 @default.
• W1777661785 cites W2399195461 @default.
• W1777661785 cites W2399255134 @default.
• W1777661785 cites W2407104316 @default.
• W1777661785 cites W2416543635 @default.
• W1777661785 cites W2929130365 @default.
• W1777661785 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10430061" @default.
• W1777661785 hasPublicationYear "1999" @default.
• W1777661785 type Work @default.
• W1777661785 sameAs 1777661785 @default.
• W1777661785 citedByCount "24" @default.
• W1777661785 countsByYear W17776617852015 @default.
• W1777661785 countsByYear W17776617852017 @default.
• W1777661785 countsByYear W17776617852022 @default.
• W1777661785 countsByYear W17776617852023 @default.
• W1777661785 crossrefType "journal-article" @default.
• W1777661785 hasAuthorship W1777661785A5002037553 @default.
• W1777661785 hasAuthorship W1777661785A5005738281 @default.
• W1777661785 hasAuthorship W1777661785A5008690308 @default.
• W1777661785 hasAuthorship W1777661785A5011905014 @default.
• W1777661785 hasAuthorship W1777661785A5015548619 @default.
• W1777661785 hasAuthorship W1777661785A5038259200 @default.
• W1777661785 hasAuthorship W1777661785A5052493398 @default.
• W1777661785 hasAuthorship W1777661785A5058784740 @default.
• W1777661785 hasAuthorship W1777661785A5060360003 @default.
• W1777661785 hasAuthorship W1777661785A5060438424 @default.
• W1777661785 hasAuthorship W1777661785A5071938679 @default.
• W1777661785 hasAuthorship W1777661785A5077260725 @default.
• W1777661785 hasAuthorship W1777661785A5079101064 @default.
• W1777661785 hasAuthorship W1777661785A5080900202 @default.
• W1777661785 hasConcept C112705442 @default.
• W1777661785 hasConcept C121608353 @default.
• W1777661785 hasConcept C126322002 @default.
• W1777661785 hasConcept C2776694085 @default.
• W1777661785 hasConcept C2777063308 @default.
• W1777661785 hasConcept C2777389519 @default.
• W1777661785 hasConcept C2778239845 @default.
• W1777661785 hasConcept C2780580376 @default.
• W1777661785 hasConcept C2780964509 @default.
• W1777661785 hasConcept C2781413609 @default.
• W1777661785 hasConcept C31760486 @default.
• W1777661785 hasConcept C71924100 @default.
• W1777661785 hasConcept C98274493 @default.
• W1777661785 hasConceptScore W1777661785C112705442 @default.
• W1777661785 hasConceptScore W1777661785C121608353 @default.
• W1777661785 hasConceptScore W1777661785C126322002 @default.
• W1777661785 hasConceptScore W1777661785C2776694085 @default.
• W1777661785 hasConceptScore W1777661785C2777063308 @default.

• next